← FDA DRUG APPROVALS

FDA BLA · BLA125160

CIMZIA

certolizumab pegol

Sponsor: UCB INC

APPLICATION
BLA125160
TYPE
BLA
ORIGINAL APPROVAL
2008-04-22
LATEST ACTION
2025-09-23
ROUTE
SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

CIMZIAPrescription
CERTOLIZUMAB PEGOL 200MG · INJECTABLE · INJECTION

Approval history

2025-09-23Labeling · Supplement 315 · standardLetterAP
2024-09-13Efficacy · Supplement 275 · standardLabelAP
2023-11-08Labeling · Supplement 309 · standardLetterAP
2022-12-22Efficacy · Supplement 305 · standardLetterAP
2019-09-06Labeling · Supplement 293 · standardLetterAP
2019-03-28Efficacy · Supplement 237 · standardLetterAP
2019-02-27Labeling · Supplement 289 · standardLetterAP
2018-06-14Manufacturing (CMC) · Supplement 279AP
2018-05-24Efficacy · Supplement 283 · standardLabelAP
2018-03-20Labeling · Supplement 281 · standardLabelAP
2018-03-16Manufacturing (CMC) · Supplement 286AP
2017-01-04Labeling · Supplement 270 · standardLabelAP
2016-04-28Labeling · Supplement 241 · standardLabelAP
2016-02-26Labeling · Supplement 266 · standardAP
2016-02-03Labeling · Supplement 268 · standardLetterAP
2015-10-19Labeling · Supplement 264 · standardLabelAP
2013-10-17Efficacy · Supplement 215 · standardReviewAP
2013-09-27Efficacy · Supplement 213 · standardReviewAP
2012-11-15Labeling · Supplement 189 · standardLabelAP
2012-10-05Labeling · Supplement 186 · standardLabelAP
2012-10-05Labeling · Supplement 192 · standardLabelAP
2012-08-29Labeling · Supplement 180 · standardLabelAP
2012-08-02Labeling · Supplement 142 · standardLabelAP
2012-04-17Efficacy · Supplement 174 · standardLabelAP
2011-09-14Labeling · Supplement 152 · standardAP
2011-09-07Labeling · Supplement 157 · standardLetterAP
2011-07-26Labeling · Supplement 155 · standardAP
2010-12-21Labeling · Supplement 122 · standardAP
2010-10-06Labeling · Supplement 126 · standardLetterAP
2010-07-29Labeling · Supplement 111 · standardLabelAP
2009-11-18Labeling · Supplement 92 · standardLetterAP
2009-05-13Efficacy · Supplement 80 · standardReviewAP
2008-12-31Labeling · Supplement 38 · standardLetterAP
2008-12-22Labeling · Supplement 36 · standardAP
2008-04-22Type 1 - New Molecular Entity · Original · standardSummary ReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →